Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study

Estelle Guiard, Bénédicte Lelievre, Magali Rouyer, Frank Zerbib, Bertrand Diquet, Francis Mégraud, François Tison, Emmanuelle Bignon, Régis Lassalle, Cécile Droz-Perroteau, Nicholas Moore and Patrick Blin ()
Additional contact information
Estelle Guiard: Bordeaux PharmacoEpi, University of Bordeaux
Bénédicte Lelievre: CHU Angers
Magali Rouyer: Bordeaux PharmacoEpi, University of Bordeaux
Frank Zerbib: CHU Bordeaux, University of Bordeaux
Bertrand Diquet: CHU Angers
Francis Mégraud: CHU Bordeaux, French National Reference Center for Helicobacters
François Tison: CHU Bordeaux, University of Bordeaux
Emmanuelle Bignon: Bordeaux PharmacoEpi, University of Bordeaux
Régis Lassalle: Bordeaux PharmacoEpi, University of Bordeaux
Cécile Droz-Perroteau: Bordeaux PharmacoEpi, University of Bordeaux
Nicholas Moore: Bordeaux PharmacoEpi, University of Bordeaux
Patrick Blin: Bordeaux PharmacoEpi, University of Bordeaux

Drug Safety, 2019, vol. 42, issue 8, No 6, 993-1003

Abstract: Abstract Introduction A fixed-dose association of bismuth subcitrate, metronidazole and tetracycline (BMT) (Pylera®, Allergan, NJ, USA) was made available in France in 2013 for the eradication of Helicobacter pylori. Due to a historical issue of bismuth encephalopathy, the French Health Authorities requested a study of blood and plasma bismuth concentrations with BMT in daily practice. Aims The aim of the study was to measure eventual bismuth accumulation and neurological toxicity in patients prescribed BMT. Methods Patients initiating BMT for H. pylori between March 2014 and December 2015 were included. A blood sample was taken before first BMT intake and 24 h after the last intake, for assay of bismuth. A concentration > 50 μg/L was considered abnormal. Neurological complaints were assessed at inclusion, at the end of the 10-day treatment course, and 28 days later. Results 202 patients were included, of whom 190 took at least one dose of BMT, and 167 provided both required blood samples. Mean blood bismuth concentrations after the BMT course were 16.9 μg/L (95% confidence interval 15.6–18.3). Concentrations were > 50 μg/L (56.0 μg/L and 50.9 μg/L) in two elderly patients, one of whom presented mild, transient memory impairment during treatment. Non-serious neurological symptoms occurred in 20% of all patients and treatment failure was documented in 5% of patients. Conclusions In this study measuring blood bismuth concentrations in real-life practice, in 50 μg/L. No serious neurological adverse events were observed. Study registration EU-PAS register EUPAS3142 at www.encepp.eu ; ENCePP study seal.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00821-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:8:d:10.1007_s40264-019-00821-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00821-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().